Commentary on "KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer"
| Errataetall: |
CommentOn: Cancer Res. 2006 Apr 15;66(8):3992-5. - PMID 16618717 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Cancer research - 76(2016), 15 vom: 01. Aug., Seite 4309-10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Benjamin, Laura E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 26.10.2017 Date Revised 02.12.2018 published: Print CommentOn: Cancer Res. 2006 Apr 15;66(8):3992-5. - PMID 16618717 Citation Status MEDLINE |
|---|
| doi: |
10.1158/0008-5472.CAN-16-1871 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM26302413X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM26302413X | ||
| 003 | DE-627 | ||
| 005 | 20231224202954.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/0008-5472.CAN-16-1871 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0876.xml |
| 035 | |a (DE-627)NLM26302413X | ||
| 035 | |a (NLM)27480959 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Benjamin, Laura E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Commentary on "KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer" |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.10.2017 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Cancer Res. 2006 Apr 15;66(8):3992-5. - PMID 16618717 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
| 650 | 7 | |a ras Proteins |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a Cetuximab |2 NLM | |
| 650 | 7 | |a PQX0D8J21J |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research |d 1945 |g 76(2016), 15 vom: 01. Aug., Seite 4309-10 |w (DE-627)NLM000001740 |x 1538-7445 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2016 |g number:15 |g day:01 |g month:08 |g pages:4309-10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/0008-5472.CAN-16-1871 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2016 |e 15 |b 01 |c 08 |h 4309-10 | ||